SCHEMBL4290751

SCHEMBL4290751

Cc1ccc(N)cc1CN1CCN(C2CC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.48
MAPK1 P28482 1/20 0.48
ACHE P22303 3/20 0.44
NR1H2 P55055 1/20 0.42
TRPV6 Q9H1D0 4/20 0.40
MAPT P10636 2/20 0.38
GAA P10253 1/20 0.38
RAD52 P43351 1/20 0.38
GFER P55789 1/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MEN1 O00255 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
DRD2 P14416 1/20 0.38
CHRM3 P20309 1/20 0.38
ADRA1D P25100 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12553047 0.81 KMT2A (0.60) KMT2AMAPK1ACHENR1H2MAPT
SCHEMBL3396724 0.81 NR1H2 (0.60) KMT2AMAPK1ACHENR1H2MAPT
SCHEMBL4283790 0.80 KMT2A (0.50) KMT2AMAPK1ACHEMAPTGAA
SCHEMBL29182981 0.80 ACHE (0.63) KMT2AMAPK1ACHENR1H2MAPT
SCHEMBL22172257 0.79 KDM4E (0.45) ACHENR1H2TRPV6SMN1; SMN2
SCHEMBL27804070 0.78 KMT2A (0.49) KMT2AMAPK1ACHENR1H2MAPT
SCHEMBL3399817 0.77 CYP2A13 (0.61) KMT2AMAPK1ACHEMAPTGAA
SCHEMBL274890 0.76 NR1H2 (0.69) KMT2AACHENR1H2TRPV6GAA
SCHEMBL29958956 0.76 NR1H2 (0.69) KMT2AACHENR1H2TRPV6GAA
SCHEMBL21280252 0.76 KMT2A (0.50) KMT2AMAPK1ACHENR1H2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101981036-B Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors NOVARTIS AG 2013-09-04 CN disclosed
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 US disclosed
CN-101981036-A Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors NOVARTIS AG 2011-02-23 CN disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 KMT2A 1885/4885MAPK1 13/4885ACHE 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.